FDA Report On Its 50 Years In Cannabis Research, Signals A Boost In Medical Marijuana Prospects - Jazz Pharmaceuticals (NASDAQ:JAZZ)

Researchers with the Food and Drug Administration (FDA) reported Wednesday on the agency’s 50 years of experience with marijuana research. In an article titled “FDA’s 50

Related Keywords

Cassandra Taylor ,Xavier Becerra ,Schuyler Pruyn ,Quality Considerations For Clinical Research ,Human Services ,Jazz Pharmaceuticals Jazzepidiolex ,Drug Administration ,Drug Development ,Drug Enforcement Administration ,Cannabis Research Helping ,Support Tomorrow ,Cannabis Drug ,Secretary Xavier Becerra ,Drug Evaluation ,Jazz Pharmaceuticals ,Botanical Drug Development ,Cannabis Derived Compounds ,Quality Considerations ,Clinical Research ,